CJC-1295 Research for Growth Hormone Deficiency
An evidence-based overview of research examining CJC-1295 in the context of growth hormone deficiency. This page synthesizes findings from peer-reviewed literature.
Research Summary
CJC-1295 was developed to address the need for longer-acting GHRH analogs in growth hormone deficiency. Phase 1-2 trials demonstrated sustained elevations in GH and IGF-1 levels with once or twice-weekly dosing. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days and maintaining IGF-1 elevation for 9-11 days after a single injection. This addresses the pharmacokinetic limitations of native GHRH. However, clinical development was discontinued in 2006 after a participant death (deemed unrelated to the drug but due to pre-existing coronary disease). No approved GHRH-based therapies use CJC-1295.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Growth Hormone Deficiency
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CJC-1295 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.